Rivastigmine For Methamphetamine Dependent Individuals

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Methamphetamine abuse has been steadily increasing over the past decade. Rivastigmine is a medication that may be helpful in treating methamphetamine dependence. The purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborator: University of California, Los Angeles
• Treatments: Methamphetamine; Rivastigmine

Criteria

Inclusion Criteria:

• Speaks English

• Not seeking treatment for methamphetamine dependence at study entry

• Meets DSM-IV criteria for methamphetamine abuse or dependence

• Smokes or intravenously uses methamphetamine

• Resting pulse between 50 and 90 beats per minute within 2 days prior to study entry

• Systolic blood pressure between 85 and 150 mmHg and diastolic blood pressure between 45 and 90 mmHg within 2 days prior to study entry

• Electrocardiogram demonstrating normal sinus rhythm, normal conduction, and no clinically significant arrhythmias

• Medical history and brief physical examination demonstrating no clinically significant contraindications for study participation

Exclusion Criteria:

• History or evidence of seizures or brain injury

• Previous adverse reaction to methamphetamine

• Neurological or psychiatric disorders (e.g., psychosis, bipolar illness, or major depression)

• Organic brain disease or dementia

• History of any psychiatric disorder that requires ongoing treatment or that would make study compliance difficult

• History of suicide attempts within the 3 months prior to study entry

• Heart disease or high blood pressure

• Family history of early cardiovascular morbidity or mortality

• Untreated or unstable medical illness, including neuroendocrine, autoimmune, liver, kidney, or active infectious disease

• HIV infected

• AIDS-defining illness

• Currently taking antiretroviral medication

• Pregnant or breastfeeding

• Unwilling to use an adequate method of contraception for the duration of the study

• History of respiratory illness (e.g., asthma, chronic coughing, and wheezing)

• Currently using alpha or beta agonists, theophylline, or other sympathomimetics